Alogabat Explained

Routes Of Administration:	Oral
Class:	α5 subunit-containing GABAA receptor positive allosteric modulator
Cas Number:	2230009-48-8
Pubchem:	134588268
Drugbank:	DB18708
Chemspiderid:	115006746
Unii:	0HPA4GK3UH
Kegg:	D12382
Chembl:	5095259
Synonyms:	GABA-Aa5 PAM; GABA-Aα5 PAM; RG-7816; RG7816; RO-7017773; RO7017773
Iupac Name:	6-5-methyl-3-(6-methylpyridin-3-yl)-1,2-oxazol-4-ylmethoxy]-N-(oxan-4-yl)pyridazine-3-carboxamide
C:	21
H:	23
N:	5
O:	4
Smiles:	CC1=NC=C(C=C1)C2=NOC(=C2COC3=NN=C(C=C3)C(=O)NC4CCOCC4)C
Stdinchi:	1S/C21H23N5O4/c1-13-3-4-15(11-22-13)20-17(14(2)30-26-20)12-29-19-6-5-18(24-25-19)21(27)23-16-7-9-28-10-8-16/h3-6,11,16H,7-10,12H2,1-2H3,(H,23,27)
Stdinchikey:	ACZCJTHHWMBFKC-UHFFFAOYSA-N

Alogabat (; developmental code names RG-7816 and RO7017773) is an α₅ subunit-containing GABA_A receptor positive allosteric modulator which is under development for the treatment of pervasive developmental disorders (e.g., autism) and Angelman syndrome.^{[1] [2] [3] [4]} It is taken by mouth.

As of June 2024, alogabat is in phase 2 clinical trials for pervasive developmental disorders and Angelman syndrome. It is under development by Roche.

See also

• Darigabat

Notes and References

1. Web site: Alogabat - Genentech . AdisInsight . 28 June 2024 . 29 October 2024.
2. Web site: Delving into the Latest Updates on RG-7816 with Synapse . Synapse . 19 September 2024 . 29 October 2024.
3. Maramai S, Benchekroun M, Ward SE, Atack JR . Subtype Selective γ-Aminobutyric Acid Type A Receptor (GABA_AR) Modulators Acting at the Benzodiazepine Binding Site: An Update . Journal of Medicinal Chemistry . 63 . 7 . 3425–3446 . April 2020 . 31738537 . 10.1021/acs.jmedchem.9b01312 .
4. Book: Stevens EB, Stephens GJ . Ion Channels as Targets in Drug Discovery: Outlook and Perspectives . Ion Channels as Targets in Drug Discovery . Springer International Publishing . Cham . 2024 . 978-3-031-52196-6 . 10.1007/978-3-031-52197-3_1 . 1–34.